MTOR and familial pancreatic carcinoma: In this phase II study, exploring the combination of capecitabine with the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer moderate treatment activity was observed with a response rate (RR) of 6.5 % and an overall survival (OS) of 8.9 months.